IMVIF Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EST
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.02
Previous CloseN/A
Volume593.00
Average Volume (3M)3.35K
Market Cap
$9.23M
Enterprise ValueN/A
Total Cash (Recent Filing)$21.21M
Total Debt (Recent Filing)$28.90M
Price to Earnings (P/E)―
Beta4444.51
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,711,637
10 Day Avg. Volume0
30 Day Avg. Volume3,351
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IMVIF FAQ
What was IMV’s price range in the past 12 months?
IMV lowest stock price was $0.01 and its highest was $0.02 in the past 12 months.
What is IMV’s market cap?
IMV’s market cap is $9.23M.
When is IMV’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were IMV’s earnings last quarter?
Currently, no data Available
Is IMV overvalued?
According to Wall Street analysts IMV’s price is currently Overvalued.
Does IMV pay dividends?
IMV does not currently pay dividends.
What is IMV’s EPS estimate?
IMV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IMV have?
IMV has 11,711,637 shares outstanding.
What happened to IMV’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IMV?
Currently, no hedge funds are holding shares in IMVIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IMV
IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---